| MedIntelliBase® NewsTips | December 2005 |
Your monthly newsletter from the
"better way to access market intelligence" people at medintellibase.com
MedIntelliBase NewsTips... A Better Way...to stay up-to-date
Table of Contents Please read below for news-worthy NewsTips and other information including: -- MedIntelliBase Introduction >> --On Line, On-Time, On Demand-- -- New Drug for the Treatment of Endovascular Disease -- Clinical Study in Endovascular Therapeutics -- Clinical Study in Cardiovascular Therapeutics -- More Information Available at www.MedIntelliBase.com! ~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~
This December issue of MedIntelliBase™ (MIB) NewsTips provides you with the late breaking NewsTips from our Cardiovascular and Endovascular Therapeutics MarketTracks. To learn more about these and many more trials and therapies please let me know - we just released our Endovascular Therapeutics MIB databases for subscription and our Cardiovascular MarketTrack was again updated in mid-December. At the request of a few of our clients we also have extended our year- end offer through January 31 to allow you ample budget review time. To introduce you to our innovative products my team and I are offering you a 40% discount on all MedIntelliBase MarketTracks. Just visit our webpage, http://www.MedIntelliBase.com/products.html, to learn more about each of our products, and call me to place this special order. I hope you will take advantage of our limited-time offer. As always, our MedIntelliBase Team - Tyler Mittleider, Jordan Zornes, and I – think you will find great value in this information...and our extended offer. Use them in good health! May 2006 be a great year for you!
|
If you are tired of outdated, canned market research reports or databases that do not offer the intelligent insights and analysis you need...then MedIntelliBase is for you. Each month our MIB NewsTips e-newsletters will provide you with a glimpse into our up-to-date MedIntelliBase MarketTracks - capturing the most recent market, clinical research and technology intelligence. Our first MarketTracks - the Interventional Medicine Series - cover Cardiovascular, Endovascular, Carotid Artery & Stroke, and Neurovascular Therapeutics. Take a moment to learn even more about this exciting new way to access up-to-date information and intelligence>> |
NM-702 is a new antiplatelet agent in development for patients with Peripheral Artery Disease (PAD). It is currently being evaluated in a Phase II clinical study (see below) for the treatment of intermittent claudication. Nissan Chemical Industries and Taisho Pharmaceutical Co., Ltd., both operating in Japan, are collaborating on the development of this new drug. NM-702 is described as a powerful inhibitor of phosphodiesterase (PDE) III & V and thromboxane A2 (TXA2) synthesis. |
The US-based "Efficacy and Safety of NM-702 Tablets for the Treatment of Intermittent Claudication" study is currently evaluating NM-702 in patients 50 years or older with stable, symptomatic, intermittent claudication caused by lower extremity atherosclerotic disease. This randomized, double- blind, placebo-controlled study is designed to evaluate the drug's safety and efficacy in 390 patients when taken twice daily (4 mg and/or 8 mg BID) for 24 weeks to determine if peak walking time is improved. Data from this study should be available following its expected completion in April 2006. |
The SPIRIT III trial - "A Clinical Evaluation of the XIENCE(TM) V Everolimus Eluting Coronary Stent System (CSS) in the Treatment of Subjects with De Novo Native Coronary Artery Lesions" - is currently enrolling an expected 1,380 patients to evaluate the XIENCE V everolimus-eluting coronary artery stent system from Guidant Corporation. The objective of this study is to demonstrate the safety and efficacy of the XIENCE V stent system compared with Boston Scientific's TAXUS Express2 paclitaxel-eluting coronary stent system in a large scale pivotal study. Patients will be randomized in two US arms, non- randomized in three US arms, and the study includes a non-randomized arm in Japan. The primary endpoint is in-segment late lumen loss (LLL) at 240 days, and a major secondary endpoint is ischemia-driven target vessel failure (TVF) at 270 days. |
You can find more information about the summaries above and many more technologies and clinical studies in MedIntelliBase >> visit our website at www.MedIntelliBase.com We will be pleased to help you access the critical intelligence you need to make informed product development and business investment decisions. |
If you have a medical technology-related question, call or email me, Vicky Hunsicker Sanko. If I don't know the answer, I'll find out. You can find other related services at our sister division's website at The Next Phase Consultancy's Home Page.
We also publish a free monthly e-newsletter on device discovery, definition and development as well as related customer needs analysis, market research, and business development issues called NextTip(TM) Insight. To subscribe send an email to one of us with "Subscribe to NextTip Insight" in the subject line. See past issues at http://www.thenextphase.com/consultancy/pub_newsletter.html. |